<scp>mRECIST</scp> to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase <scp>II</scp> trials comparing nintedanib vs sorafenib

Abstract

Response according to RECIST or mRECIST is associated with improved survival and should be considered as a valid endpoint for use in HCC clinical trials.